Report Details:
15 Companies Covered
90 Pages
Cholesterol Test Market: Increasing Prevalence of Cardiovascular Diseases and Obesity to Boost Market Growth at a Healthy CAGR of 8.32% through 2035
Market Overview
The global cholesterol test market is projected to grow significantly from USD 7.26 billion in 2024 to USD 17.48 billion by 2035, registering a CAGR of 8.32% during the forecast period.
This robust growth is primarily attributed to the rising prevalence of cardiovascular diseases, increasing health awareness, and technological advancements in diagnostic solutions.
Cholesterol testing plays a vital role in preventive healthcare by enabling early detection of lipid disorders and reducing the risk of cardiac complications. The growing emphasis on proactive health management and regular check-ups has further fueled the demand for cholesterol testing across both developed and developing economies.
Market Drivers
The rising incidence of cardiovascular diseases and obesity has emerged as a key factor propelling the cholesterol test market. Health organizations worldwide emphasize routine cholesterol testing as part of preventive healthcare programs, especially among individuals at risk of heart disease.
The Centers for Disease Control and Prevention (CDC) recommends regular screening for children aged 9–11 and young adults aged 17–21, reinforcing the importance of early detection.
Technological advancements have also transformed the cholesterol testing landscape. The introduction of point-of-care devices, home testing kits, and AI-driven diagnostics has made testing more accessible and accurate.
The increasing integration of digital tools in diagnostic processes allows patients to monitor their cholesterol levels conveniently, promoting self-care and timely intervention.
Furthermore, government-led health awareness campaigns and initiatives focused on cardiovascular wellness continue to support market expansion by encouraging routine testing and preventive measures.
The aging global population and the growing burden of lifestyle-related disorders further accelerate market growth. Older adults are particularly vulnerable to cholesterol imbalances, driving the need for frequent testing and monitoring.
Rising healthcare expenditure and improved diagnostic infrastructure in emerging economies such as India and China also contribute to market development. Together, these factors underline a strong foundation for sustained growth in the cholesterol test market through 2035.
Segment Insights
Based on product type, the market is segmented into test kits and test strips. The test kits segment dominated the market in 2022 and is expected to maintain its lead during the forecast period.
This dominance can be attributed to the development of advanced, easy-to-use testing kits that allow patients and healthcare professionals to perform cholesterol tests more efficiently. The growing adoption of portable diagnostic tools and point-of-care systems supports the expansion of this segment.
By test type, the total cholesterol test category held the largest share in 2022 and is expected to continue leading through 2035. Increased awareness regarding routine cholesterol monitoring, coupled with the rising prevalence of diabetes and cardiovascular conditions, has strengthened the demand for total cholesterol testing.
These tests are widely recommended by healthcare professionals for their effectiveness in detecting early signs of lipid imbalances. Based on end-user, diagnostic centers dominated the market in 2022 and are expected to remain the fastest-growing segment.
The rise in preventive health check-ups and improved accessibility to diagnostic facilities has significantly boosted this segment’s growth. Homecare testing is also gaining traction, driven by the availability of self-testing devices and an increasing preference for convenience-based healthcare solutions.
In the distribution channel segment, the over-the-counter category held a dominating position. On the other hand, the prescription-based category is likely to gain traction as the market evolves.
Hospitals and clinics are likely to be the largest revenue generators for the ecosystem. Diagnostic centers and homecare categories occupy a respectable market share, owing to the changing consumer demand.
Regional Insights
Regionally, North America accounted for the largest market share in 2022, holding 45.8% of the market, which translated into USD 2.8 billion of valuation, and is expected to continue its dominance throughout the forecast period.
The region’s growth is driven by a strong healthcare infrastructure, high prevalence of cardiovascular diseases, and widespread adoption of preventive health measures.
The United States remains a key contributor, with a significant number of individuals undergoing regular cholesterol screening due to rising awareness and supportive healthcare policies.
Europe represented the second-largest regional market, fueled by rising awareness of preventive healthcare and advancements in diagnostic technologies. Countries such as the UK and Germany are leading contributors, with growing investments in cholesterol testing devices and laboratory infrastructure.
The Asia-Pacific region is expected to witness the fastest growth during the forecast period, supported by an increasing population base, rising healthcare expenditure, and improving diagnostic capabilities.
Emerging economies such as China and India are experiencing rapid growth in healthcare infrastructure, facilitating broader access to cholesterol testing. The region’s expanding middle-class population and focus on health consciousness are also key growth enablers.
Competitive Landscape
The global cholesterol test market is characterized by strong competition, with key players investing in research and development to enhance their product portfolios.
Major companies include Quest Diagnostics Incorporated, Randox Laboratories Ltd., Hoffmann-La Roche AG, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Eurofins Scientific, and PTS Diagnostics.
These companies are focusing on strategic collaborations, new product launches, and technological innovation to strengthen their market presence.
Recent industry developments highlight ongoing advancements in cholesterol testing technology. In 2024, Abbott launched its next-generation Alinity cholesterol testing system, while Roche received FDA clearance for its Cobas Lipid Panel.
Siemens Healthineers partnered with CVS Health to expand in-store cholesterol testing across the United States, and Bio-Rad Laboratories acquired LipidSense Diagnostics to strengthen its diagnostics portfolio. These strategic initiatives collectively contribute to expanding accessibility, accuracy, and efficiency in cholesterol testing.
Key Findings
- The global cholesterol test market is anticipated to grow from USD 7.26 billion in 2024 to USD 17.48 billion by 2035, at a CAGR of 8.32%.
- Rising cases of cardiovascular diseases, obesity, and diabetes remain the primary drivers of market expansion.
- Technological innovations in home-based and point-of-care testing devices are enhancing accessibility and patient engagement.
- Diagnostic centers and hospitals remain key end-users, supported by the increasing demand for routine health check-ups.
- North America led the market, which held 45.8% of the market share, while Asia-Pacific is expected to record the highest growth rate due to improving healthcare infrastructure.
- Major companies are focusing on partnerships, acquisitions, and R&D investments to strengthen their global footprint and introduce advanced testing solutions.